Exchange: NYSE·Updated 03:35 PM EDT
EW logo

EWEdwards Lifesciences Corp

$92.10
$1.64
(1.81%)
Today
EarningsJul 23
Mkt Cap$52.09B
Vol2.16M
News
all
press releases
Can ISRG's 'Quintuple Aim' Strategy Continue to Justify Premium Pricing?
Intuitive Surgical's Quintuple Aim strategy is driving premium pricing as da Vinci 5 adoption grows, with innovation-led revenue growth outpacing procedure growth.
Zacks
News Placeholder
More News
News Placeholder
Edwards Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data...
Business Wire
News Placeholder
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
Globus Medical faces inflation, geopolitical and currency pressures as rising costs and FX losses cloud margin flexibility and international growth.
Zacks
News Placeholder
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device
CMS proposes easing TAVR coverage rules and expanding access, a move analysts say could strengthen Edwards Lifesciences' market position.read more...
Benzinga
News Placeholder
Should You Continue to Hold EW Stock in Your Portfolio?
Edwards gains from strong TMTT growth, RESILIA adoption and expanding TAVR use, but macro pressures and currency swings remain key risks.
Zacks
News Placeholder
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
OPKO Health (OPK) Up 17.1% Since Last Earnings Report: Can It Continue?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Boston Scientific Bets on WATCHMAN to Drive Structural Heart Growth
WATCHMAN's 19% growth and trial wins bolster Boston Scientific's push to expand its addressable market from 5M to 20M patients worldwide.
Zacks
News Placeholder
Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise
Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise...
Yahoo! Finance: News
News Placeholder
Edwards Lifesciences Appoints Theodora Mistras As Chief Financial Officer
(RTTNews) - Edwards Lifesciences Corporation (EW) said that it has appointed Theodora Mistras as chief financial officer effective at the end of May...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.